RANKL showed no significant difference with CML treatment (1.50, 95% CI: 0.48-1.72, p = 0.19) compared to OC (1.15, 95% CI: 0.89 - 1.41). The gene discussed is TNFSF11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.